Supplementary Figure S2 from The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer

作者：Michael Cecchini, Sae‐Won Han, Soo Hyun Lee, Keun‐Wook Lee, Scott Kopetz, Jonathan D. Mizrahi, Yong Sang Hong, François Ghiringhelli, Antoîne Italiano, David Tougeron, Brandon Beagle, Mathew Boakye, Tingting Zhao, Vivek Khemka, Zev A. Wainberg · 年份：2026 · DOI：10.1158/1078-0432.32845411 · 研究领域：Colorectal Cancer Treatments and Studies、PARP inhibition in cancer therapy、Cancer Immunotherapy and Biomarkers

<p>OS if crossover from regorafenib to EZFB had not been permitted, using the RPSFT model. A key assumption of the RPSFT model is that the experimental therapy (EZFB) has the same treatment effect, regardless of whether the experimental therapy is given from the initial randomization or from the time of crossover. EZFB, original group that received etrumadenant and zimberelimab with mFOLFOX-6 and bevacizumab; mFOLFOX-6, modified FOLFOX-6; OS, overall survival; rego(o), original regorafenib group; rego(r), regorafenib group with RPSFT model; RPSFT, rank-preserving structural failure model. aHazard ratio and 95% CIs were calculated using a Cox model, stratified by geographic region.</p>